These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 25034785)

  • 1. Elimination of quiescent/slow-proliferating cancer stem cells by Bcl-XL inhibition in non-small cell lung cancer.
    Zeuner A; Francescangeli F; Contavalli P; Zapparelli G; Apuzzo T; Eramo A; Baiocchi M; De Angelis ML; Biffoni M; Sette G; Todaro M; Stassi G; De Maria R
    Cell Death Differ; 2014 Dec; 21(12):1877-88. PubMed ID: 25034785
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Histone acetyltransferase inhibitor CPTH6 preferentially targets lung cancer stem-like cells.
    Di Martile M; Desideri M; De Luca T; Gabellini C; Buglioni S; Eramo A; Sette G; Milella M; Rotili D; Mai A; Carradori S; Secci D; De Maria R; Del Bufalo D; Trisciuoglio D
    Oncotarget; 2016 Mar; 7(10):11332-48. PubMed ID: 26870991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Bcl-xL inhibitor, ABT-737, efficiently induces apoptosis and suppresses growth of hepatoma cells in combination with sorafenib.
    Hikita H; Takehara T; Shimizu S; Kodama T; Shigekawa M; Iwase K; Hosui A; Miyagi T; Tatsumi T; Ishida H; Li W; Kanto T; Hiramatsu N; Hayashi N
    Hepatology; 2010 Oct; 52(4):1310-21. PubMed ID: 20799354
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Bcl-xL inhibition by molecular-targeting drugs sensitizes human pancreatic cancer cells to TRAIL.
    Hari Y; Harashima N; Tajima Y; Harada M
    Oncotarget; 2015 Dec; 6(39):41902-15. PubMed ID: 26506422
    [TBL] [Abstract][Full Text] [Related]  

  • 5. ABT-737 Synergizes with Cisplatin Bypassing Aberration of Apoptotic Pathway in Non-small Cell Lung Cancer.
    Kim EY; Jung JY; Kim A; Chang YS; Kim SK
    Neoplasia; 2017 Apr; 19(4):354-363. PubMed ID: 28319809
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737.
    Lin X; Morgan-Lappe S; Huang X; Li L; Zakula DM; Vernetti LA; Fesik SW; Shen Y
    Oncogene; 2007 Jun; 26(27):3972-9. PubMed ID: 17173063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel small-molecule inhibitors of Bcl-XL to treat lung cancer.
    Park D; Magis AT; Li R; Owonikoko TK; Sica GL; Sun SY; Ramalingam SS; Khuri FR; Curran WJ; Deng X
    Cancer Res; 2013 Sep; 73(17):5485-96. PubMed ID: 23824742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A small-molecule inhibitor of Bcl-XL potentiates the activity of cytotoxic drugs in vitro and in vivo.
    Shoemaker AR; Oleksijew A; Bauch J; Belli BA; Borre T; Bruncko M; Deckwirth T; Frost DJ; Jarvis K; Joseph MK; Marsh K; McClellan W; Nellans H; Ng S; Nimmer P; O'Connor JM; Oltersdorf T; Qing W; Shen W; Stavropoulos J; Tahir SK; Wang B; Warner R; Zhang H; Fesik SW; Rosenberg SH; Elmore SW
    Cancer Res; 2006 Sep; 66(17):8731-9. PubMed ID: 16951189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined antitumor effect of γ-secretase inhibitor and ABT-737 in Notch-expressing non-small cell lung cancer.
    Sakakibara-Konishi J; Ikezawa Y; Oizumi S; Kikuchi J; Kikuchi E; Mizugaki H; Kinoshita I; Dosaka-Akita H; Nishimura M
    Int J Clin Oncol; 2017 Apr; 22(2):257-268. PubMed ID: 27816990
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Therapeutic efficacy of ABT-737, a selective inhibitor of BCL-2, in small cell lung cancer.
    Hann CL; Daniel VC; Sugar EA; Dobromilskaya I; Murphy SC; Cope L; Lin X; Hierman JS; Wilburn DL; Watkins DN; Rudin CM
    Cancer Res; 2008 Apr; 68(7):2321-8. PubMed ID: 18381439
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin.
    Witham J; Valenti MR; De-Haven-Brandon AK; Vidot S; Eccles SA; Kaye SB; Richardson A
    Clin Cancer Res; 2007 Dec; 13(23):7191-8. PubMed ID: 18056200
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Directed elimination of senescent cells by inhibition of BCL-W and BCL-XL.
    Yosef R; Pilpel N; Tokarsky-Amiel R; Biran A; Ovadya Y; Cohen S; Vadai E; Dassa L; Shahar E; Condiotti R; Ben-Porath I; Krizhanovsky V
    Nat Commun; 2016 Apr; 7():11190. PubMed ID: 27048913
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of Bcl-xL by ABT-737 enhances chemotherapy sensitivity in neurofibromatosis type 1-associated malignant peripheral nerve sheath tumor cells.
    Lee SJ; Park HJ; Kim YH; Kim BY; Jin HS; Kim HJ; Han JH; Yim H; Jeong SY
    Int J Mol Med; 2012 Aug; 30(2):443-50. PubMed ID: 22664653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells.
    Abed MN; Abdullah MI; Richardson A
    J Ovarian Res; 2016 Apr; 9():25. PubMed ID: 27080533
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined inhibition of Notch signaling and Bcl-2/Bcl-xL results in synergistic antimyeloma effect.
    Li M; Chen F; Clifton N; Sullivan DM; Dalton WS; Gabrilovich DI; Nefedova Y
    Mol Cancer Ther; 2010 Dec; 9(12):3200-9. PubMed ID: 21159606
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism.
    Rahmani M; Aust MM; Attkisson E; Williams DC; Ferreira-Gonzalez A; Grant S
    Cancer Res; 2013 Feb; 73(4):1340-51. PubMed ID: 23243017
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.
    Lucas KM; Mohana-Kumaran N; Lau D; Zhang XD; Hersey P; Huang DC; Weninger W; Haass NK; Allen JD
    Clin Cancer Res; 2012 Feb; 18(3):783-95. PubMed ID: 22173547
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Induction of Noxa sensitizes human colorectal cancer cells expressing Mcl-1 to the small-molecule Bcl-2/Bcl-xL inhibitor, ABT-737.
    Okumura K; Huang S; Sinicrope FA
    Clin Cancer Res; 2008 Dec; 14(24):8132-42. PubMed ID: 19088028
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer.
    Wesarg E; Hoffarth S; Wiewrodt R; Kröll M; Biesterfeld S; Huber C; Schuler M
    Int J Cancer; 2007 Dec; 121(11):2387-94. PubMed ID: 17688235
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of Mcl-1 with the pan-Bcl-2 family inhibitor (-)BI97D6 overcomes ABT-737 resistance in acute myeloid leukemia.
    Pan R; Ruvolo VR; Wei J; Konopleva M; Reed JC; Pellecchia M; Andreeff M; Ruvolo PP
    Blood; 2015 Jul; 126(3):363-72. PubMed ID: 26045609
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.